Search Results for “Local peer support group” - Page 39

Our Partners

We are proud to work collaboratively with a number of corporate partners to enable our community to live fulfilled lives today as well as supporting the pharmaceutical industry in their mission to develop potential new treatments.

Gift aid illustration showing that £1 grows to £1.25 with gift aid

Gift Aid Declaration

Completing this form will enable Retina UK to claim tax back on eligible donations. It means that for every £1 you donate to Retina UK we can claim back 25p at no extra cost to you.

Poster with details of 'Supporting Retina UK and what it can do for you' with an image of three sets of hands holding a heart shape made up of jigsaw pieces in various colours

Webinar: Supporting Retina UK and what it can do for you

Our speakers tell us about the many positive impacts fundraising has had for them, including for their emotional wellbeing, and the many surprises along the way.

Meet our community: James Clarke

Aged 20, James was diagnosed with retinitis pigmentosa at a routine eye appointment in September 2015 and registered partially sighted, just prior to buying his first car and taking his driving test.

Peak District Challenge

Walk, jog or run 25, 50 or 100km from the Bakewell Base Camp and take in Derbyshire’s finest scenery.

Potential drug targets identified for RP

A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.

ProQR announces suspension of LCA10 and USH2A clinical trials

Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.

News

Genetic testing: an essential topic for discussion with the IRD community

As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.